03 Jun 2024 Research & Development Spotlight Series – Episode 3 Blogs | Investors | R&D Spotlights Series | Therapeutics
23 May 2024 Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial Investors | Therapeutics
25 Apr 2024 Research and Development Spotlight Series – Episode 2 Blogs | Investors | R&D Spotlights Series | Therapeutics
09 Apr 2024 Christina Coughlin – AACR 2024 – AVA6000 data presentation Blogs | Investors | Therapeutics
09 Apr 2024 Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses Investors | Therapeutics
27 Mar 2024 Research and Development Spotlight Series – Episode 1 Blogs | Investors | R&D Spotlights Series | Therapeutics
06 Mar 2024 Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Therapeutics
19 Jan 2024 Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development Investors | Therapeutics